Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Concurrent chemoradiation in lung cancer].

Nicolas Girard1, Françoise Mornex

  • 1Département de radiothérapie-oncologie, Centre hospitalier Lyon-Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite Cedex.

Bulletin Du Cancer
|January 7, 2006
PubMed
Summary

Concurrent chemoradiation is the standard for advanced non-small cell lung cancer. Optimizing radiation and chemotherapy can improve local control and survival, with ongoing trials exploring novel agents and schedules.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy.

Clinical and translational radiation oncology·2026
Same author

The French Reirradiation Team for Research and Treatment (FReTREAT): A national collaborative model by Unitrad for advancing reirradiation research, education, and clinical practice in France.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same author

International Thymic Malignancy Interest Group Standard Definitions, Policies, and Reporting Measures for Thymic Epithelial Tumors.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2025
Same author

Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST Study.

Oncology and therapy·2025
Same author

Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis.

British journal of cancer·2025
Same author

Overall Survival with Amivantamab-Lazertinib in <i>EGFR</i>-Mutated Advanced NSCLC.

The New England journal of medicine·2025

Area of Science:

  • Thoracic Oncology
  • Radiation Oncology
  • Medical Oncology

Context:

  • Concurrent chemoradiation is the established standard for locally advanced non-small cell lung cancer (NSCLC).
  • It is used as definitive therapy for unresectable tumors and neoadjuvantly for potentially resectable tumors.
  • Optimal sequencing and integration of chemotherapy with radiation remain areas of active investigation.

Purpose:

  • To review the current role and future directions of chemoradiation in thoracic malignancies.
  • To explore strategies for enhancing local control and survival in non-small cell lung cancer.
  • To highlight the evolving landscape of chemoradiation, including novel agents and radiation techniques.

Summary:

  • Concurrent chemoradiation is the standard of care for locally advanced non-small cell lung cancer (NSCLC).

Related Experiment Videos

  • Strategies to improve outcomes include optimized radiation fractionation, escalated doses, and less toxic chemotherapy agents.
  • Induction chemoradiation followed by surgery is feasible and effective in select patients.
  • Early concurrent chemoradiation with platinum and etoposide is standard for localized small cell lung cancer (SCLC).

    • Impact:

    • Concurrent chemoradiation remains a highly promising therapeutic strategy in thoracic oncology.
    • Ongoing clinical trials are investigating modern radiation schedules combined with newer chemotherapy agents.
    • Advances in chemoradiation aim to improve local control, survival rates, and patient tolerance.